The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease
Many cancer patients with autoimmune disease are excluded from studies of immune checkpoint inhibitors due to hypothesis of the association of this treatment with immune-related adverse events